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Gdansk, PolandAbstractMinor drug-resistant variants may preexist in every subject infected
with hepatitis B virus (HBV). However, understanding the dynamic
of genotypic evolution within the HBV population requires
accurately following allele frequencies through time. We used
MALDI-TOF MS (matrix-assisted laser desorption-ionization
time-of-ﬂight mass spectrometry) for localization and quantitative
allele frequency detection to investigate preexisting HBV
quasispecies and the genotypic evolution of drug-resistant
variants during nucleos(t)ide analogue therapy. We found a
signiﬁcant difference between the genotypic evolution of drug-
resistant variants depending on response to treatment.
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krzysztof.bielawski@biotech.ug.edu.pl (K.P. Bielawski)Hepatitis B virus (HBV) displays high genetic variability, which is
the primary reason of the emergence and selection of drug-
resistant variants harboring amino acid substitutions in theMicrobiol Infect 2015; 21: 288.e1–288.e4
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.10.004viral polymerase. The major causes of HBV heterogeneity
include the error-prone viral reverse transcriptase, which
generates an average about 1.4 to 3.2 × 10−5 substitutions per
site per year and a high kinetic of virion [1,2]. As a conse-
quence, point mutations, including those associated with drug
resistance, are spontaneously generated many times every day,
even in subjects who never have received nucleos(t)ide
analogue (NA) therapy. This phenomenon of the HBV life cycle
leads to the formation of a diverse pool of closely related but
distinct genetic variants (quasispecies). Virus population
changes over time under selective pressure. Different variants
occur continuously during virus replication at different stages of
infection depending on the host immunosystem and NA ther-
apy. The most adapted of these newly generated variants are
selected in the environment on the basis of their own repli-
cation capacities, and the fast-replicating variants are likely to
become the dominant strains. However, the ﬁttest strain may
not be necessarily the previously prevalent strain. The contin-
uous production and selection of variants enables virus to evade
elimination by the immune system, resulting in persistent
infection [3–5].
Preliminary data indicate that there is a possibility of the
preexistence of natural drug-resistant variants in treatment-
naïve subjects [6]. However, little is known about variations in
the relative abundance of these mutations and if such variations
have clinical signiﬁcance. Detailed study of minor variants is
hampered by the absence of sensitive sequencing strategies
which would allow for the detection of low-frequency genomes.
However, there has been a recent advance in the identiﬁ-
cation of minor quasispecies variants. MALDI-TOF MS (matrix-
assisted laser desorption-ionization time-of-ﬂight mass spec-
trometry) has become a powerful and widespread analytical
tool in all ﬁelds of the life sciences [7]. The aim of this study was
identiﬁcation and quantitative allele frequency detection to
investigate preexisting HBV quasispecies and the genotypic
evolution of drug-resistant variants during NA therapy.
Forty-three HBV subjects who received NA monotherapy
with lamivudine (n = 24), entecavir (n = 13) or tenofovir (n = 6)
for at least 48 weeks were enrolled onto the present study. The
study group (n = 43) consisted of treatment-experienced (51%)
and treatment-naïve subjects (49%). Blood samples were stored
at initiation of treatment, and again at weeks 12 and 48. The
local ethics committee accepted the protocol of this study, and
all subjects provided written informed consent to participate in
this study.
All subjects were considered and received treatment ac-
cording to the recommendations of the Polish National Health
Service. These recommendations require the use of peg-IFN-
α2a or lamivudine (when nucleoside/nucleotide analogues areious Diseases. Published by Elsevier Ltd. All rights reserved
FIG. 1. Dynamics of viral variants during antiviral therapy (weeks 0, 12, 48) in those (a) with and (b) without response to therapy.
CMI Rybicka et al. Dynamics of HBV quasispecies 288.e2recommended) as a primary therapy in hepatitis B e antigen
(HBeAg)-negative subjects. In HBeAg-reactive subjects and
those with lamivudine-resistant strains, entecavir or tenofovir is
recommended as a ﬁrst-line therapy. Combined therapies are
rare in Poland and were allowed after the approval of a national
consultant for infectious diseases.
HBV genotyping was performed on virus DNA extracted
from 200 μL of serum samples as described elsewhere [6]. The
selected HBV variants were determined on the Mass Array
genotyping platform (Sequenom Inc., USA) in four iPLEX re-
actions at each point of time (weeks 0, 12, 48) [6]. Serologic
HBV markers (HBeAg, HBeAg, hepatitis B surface antigen),
virus load and biochemical tests were assessed every 12 weeks
for documentation of any adverse events.
The iPLEX results were analysed with TyperAnalyzer
Application (Sequenom Inc., USA) which allows for detection of
low-frequency mutations as well as allele frequency calculation.
Statistical analysis was performed by the Mann-Whitney U test
and Spearman rank correlation. A value of p <0.05 was
considered statistically signiﬁcant.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InDrug-resistant variants in the lamivudine group were
detected at treatment in 72 % (13/18) of drug-naïve and in all
drug-experienced subjects (n = 6), with an allele frequency of
1.2% to 44% and 1.2% to 100%, respectively. In the entecavir
group, resistant HBV variants were identiﬁed in both groups
(1.1% to 19.9% and 1.4% to 86%). All tenofovir-treated subjects
were drug experienced (1.4% to 56.4%).
The therapy effect was assessed 48 weeks after NA admin-
istration, according to the recommendations of the Polish
National Health Service. Subjects were classiﬁed into two
groups: those whose disease did not respond to therapy
(detectable HBV DNA) and those whose disease did respond to
therapy (undetectable HBV DNA).
We observed changes occurring in the HBV quasispecies
within 48 weeks of NA treatment (Fig. 1). The percentages of
drug-resistant variants notably increased relative to baseline in
subjects who did not respond to therapy at week 12 (p <0.01)
and week 48 (p <0.001), as well as new mutations that appeared
during NA therapy (week 12: p <0.01, week 48: p <0.0001). In
the case of the group that responded to therapy, drug-resistantfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 288.e1–288.e4
TABLE 1. Subject characteristics
Characteristic
Response
(n [ 23)
No response
(n [ 20) p*
Age (years) 41.87 51.25 0.034028
Sex (M/F) 10/13 13/7 0.167378
Baseline HBV virus load (kIU/mL)† 16487 57639 0.036747
Baseline HBeAg (positive/negative) 6/17 11/9 0.057805
Baseline ALT (IU/L)† 148 73 0.450251
Baseline AF >15% 6 14 0.011778
Naïve subjects 10 11 0.464769
Baseline no. of mutations† 3.13 2.8 0.463344
Liver biopsy inﬂammation activity† 1.76 1.88 0.488896
Liver biopsy ﬁbrosis stage† 1.89 1.71 0.814415
Increase of AF at week 12 (yes/no) 3/20 10/10 0.009715
New mutations at week 12 (yes/no) 6/17 14/6 0.004629
Loss of mutations at week 12 (yes/no) 16/7 3/17 0.001052
Increase of AF at week 48 (yes/no) 1/22 12/8 0.000096
New mutations at week 48 (yes/no) 1/22 13/7 0.000031
Loss of mutations at week 48 (yes/no) 18/5 3/17 0.000046
HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase;
AF, allele frequency.
*Mann-Whitney U test.
†Average value.
288.e3 Clinical Microbiology and Infection, Volume 21 Number 3, March 2015 CMImutants disappeared in time (p <0.01 and p <0.0001 for weeks
12 and 48, respectively). There were no signiﬁcant differences
between treatment-naïve and treatment-experienced group
(Table 1).
The efﬁcacy of antiviral therapy in this study did not depend
on liver biopsy inﬂammation activity (p 0.49) or ﬁbrosis stage (p
0.81). As has been described elsewhere, we found that lower
level of HBV DNA at the beginning of treatment (p 0.037) and
younger age (p 0.034) of subjects were associated with a higher
possibility of virologic response [8–12]. The preexistence (p
0.85) and number of HBV drug-resistant variants (p 0.46)
before treatment were not statistically signiﬁcant. However, the
baseline allele frequency of all HBV resistant mutants appeared
to be a strong predicting factor of the response to antiviral
therapy (p 0.042), especially when the percentages of mutations
was >15% (p 0.012).
In this study, we used MALDI-TOF MS to study the evolu-
tion of drug resistance and to detect minor HBV variants in 43
subjects. We characterized the dynamics of HBV quasispecies
evolution during NA therapy with low to moderate genetic
barrier antiviral drugs. Although the baseline parameters, such
as the presence and number of drug-resistant mutants, were
not different between those with virologic response and
nonresponse, our result showed that an increase in the per-
centage of drug-resistant variants at weeks 12 and 48 was
associated with response to therapy. We found very low levels
of drug resistance before therapy, but during treatment failure,
resistant viruses were effectively accumulated. When treatment
was interrupted, drug-resistant viruses disappeared rapidly in
time.
Resistant mutations have been extensively studied over the
past few years. However, less attention has been paid to the
potential role of HBV quasispecies heterogeneity on antiviralClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecttreatment outcome. Although some groups showed an asso-
ciation between high complexity of HBV population at week 4
and nonresponse to NA treatment, to our knowledge, no study
has accurately followed the allele frequencies of HBV quasis-
pecies through time [12–14]. Our study is novel in that it not
only detected the preexisting HBV quasispecies but also
measured its quantity. We trust that investigated differences in
allele frequency of HBV mutants before treatment may become
a useful factor predicting therapeutic efﬁcacy.
There is a signiﬁcant difference between the genotypic
evolution of drug-resistant variants depending on the response
to NA therapy. Furthermore, there was a marked loss of the
number and percentage of drug-resistant and wild-type variants
during treatment interruption and treatment failure, respec-
tively. Thus, monitoring of allele frequency of drug-resistant
HBV strains with the use of MALDI-TOF MS may become a
useful way to predict disease progression.Transparency declarationFinancial support was received from FP7 project MOBI4Health,
grant 316094, Ministry of Science and Higher Education, grant
2013/11/N/NZ7/00377 and Medical University of Gdansk, grant
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